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Abstract
T cell functional plasticity helps tailor antiviral immunity during different phases of infections. We tested whether, during
different phases of HBV infection, virus-specific T cells can acquire specific proinflammatory functions that could drive
granulocyte/mononuclear cell liver infiltration. Multifunctional analysis of HBV-specific T cells during acute and chronic HBV
infection revealed that HBV-specific T cells had the capacity to produce the neutrophil chemokine CXCL-8 but not IL-17.
CXCL-8 producing T cells were detectable in the liver of chronic HBV patients with active hepatitis; while in acute HBV
patients CXCL-8 production by T cells was temporally limited to the acute phase of disease, concomitant with the peak of
liver inflammation. Characterization of the conditions necessary for the development of CXCL-8 producing T cells showed a
requirement for IL-7 and IL-15 during T cell expansion. These data show that functional plasticity of virus-specific T cells
spontaneously occurs during HBV infection and that an environment rich IL-7 and IL-15 can license T cells with the ability to
produce CXCL-8 and potentially influence liver pathology.
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Introduction
Virus-specific T cells are essential for the control of viral
infections but are also implicated in triggering the inflammatory
events that are often the main cause of pathology. This is
particularly true during infection with non-cytopathic viruses such
as hepatitis B virus (HBV), which causes acute and chronic liver
inflammation; pathological conditions that can evolve into liver
cirrhosis and hepatocellular carcinoma [1]. Virus-specific T cells are
associated with control of HBV infection [2,3]. Their frequency and
function is far superior in patients who resolve HBV infection than
in subjects with chronic infection and their ability to produce anti-
viral cytokines (IFN-c and TNF-a) results in HBV clearance from
infected hepatocytes without extensive direct killing [4,5,6,7,8].
In addition to their protective role, intrahepatic activation of
HBV-specific T cells can also trigger an influx of inflammatory
granulocytes and mononuclear cells to the liver, which is the
principle cause of hepatic injury. This has been clearly
demonstrated in experimentally infected chimpanzees and in
HBV transgenic mice. Depletion of T cells in infected chimpan-
zees reduced liver inflammation but prolonged HBV infection
[2,3]. In mice, adoptively transferred HBV-specific T cells trigger
the recruitment of neutrophils and mononuclear cells that result in
liver damage [9]. Notably, depletion of neutrophils prior to T cell
transfer abolished the inflammatory infiltrate without hindering
the antiviral efficiency of HBV-specific T cells or reducing CXCL-
9 and CXCL-10 production, two chemokines induced by IFN-c
known to recruit inflammatory cells to the liver [10,11].
The ability of virus-specific T cells to orchestrate such inflam-
matory phenomenon is generally ill defined in different human
pathologies. Thus, the goal of the present study was to characterize
the inflammatory potential of virus-specific T cells, analyzing their
ability to produce different effector molecules in a non-cytopathic
human infection such as HBV. Since the role of interferon
inducible chemokines have already been investigated [12] we
focused our attention on IL-17 and CXCL-8 due to their
inflammatory potential and ability to recruit neutrophils, which
represents a key step in animal models of acute viral hepatitis.
CXCL-8, which is the primary chemotactic factor for neutrophils,
is a less well characterized T cell derived chemokine but can be
produced in large quantities by T cells [13,14] and elevated levels
of CXCL-8 are found in patients with chronic liver disease [15]
and chronic HBV patients prior to hepatic flares [16]. Likewise,
IL-17 is known to recruit neutrophils [17] and has been associated
with inflammatory diseases [18,19], including hepatic flares in
chronic HBV patients [20].
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Since T cells display a degree of functional plasticity, the
environment where T cells are activated can have a dramatic
effect on their ultimate function [21,22]. Thus, we hypothesized
that the inflammatory cytokine milieu present during HBV
infection can license T cells with the ability to produce CXCL-8
or IL-17. IL-15 is elevated in the liver of patients with active
hepatitis [23,24], has been demonstrated to induce IL-17
production [25,26] and can stimulate CXCL-8 and MCP-1
expression from monocytes [27]. In addition, IL-7 can be up-
regulated in the liver by inflammation and enhances T cell
cytotoxic activity and cytokine production [28]. Therefore, we
focused on these two cytokines, which are present in the liver
during inflammation, and are known to impact T cell function.
Our data demonstrate that HBV-specific T cells produce
CXCL-8, but not IL-17, during periods of liver inflammation and
that this functional phenotype could be induced in greater than
90% of the detectable virus-specific T cell population in acute/
resolved HBV patients by exposure to IL-7 and IL-15. We
characterized the phenotype and functional profile of CXCL-8+ T
cells and demonstrated that this functional profile could be
induced in unrelated CMV-specific T cells from healthy
individuals. Thus, cytokines present during inflammation, partic-
ularly in the liver, could license T cells with additional cytokine
profiles that contribute to tissue inflammation.
Results
HBV-specific T cell related chemokines
To begin investigating the potential contribution of additional T
cell functional profiles to liver inflammation, outside of IFN-c
induced CXCL-9 and CXCL-10, we analyzed peptide-specific
inflammatory cytokine/chemokine production from liver resident
lymphocytes of HBV patients. We tested intrahepatic T cell
responses to pools of 15mer overlapping peptides covering all
HBV proteins from six chronic active hepatitis B patients that
developed hepatocellular carcinoma (HCC). Intrahepatic lympho-
cytes, isolated from non-tumor tissue, were stimulated with
peptides overnight and culture supernatants were screened for
CXCL-8, CXCL-9, CXCL-10, CCL-5, CCL-2 as well as IL-17
and the anti-inflammatory cytokine IL-10.
Unlike resolved HBV patients that display a multi-specific T cell
response, T cells from chronic HBV patients are often exhausted or
deleted due to the persistent nature of the infection; thus, we were
only able to detect peptide-specific responses in two of the patients
tested. The profile of one patient (IHL-3) is represented in figure 1A.
CXCL-8 was the dominant inflammatory mediator detected,
followed by the IFN-c inducible chemokines CXCL-9 and CXCL-
10. Patient IHL-1 showed polymerase specific production of CXCL-
8 but CXCL-9 and CXCL-10 were undetectable (data not shown).
We did not detect peptide-specific production of IL-17 or IL-10 in
any sample and only low levels were observed following CD3/CD28
stimulation (Fig. 1A and data not shown). Figure 1B shows the
antigen-specific distribution of CXCL-8 production in patient IHL-
3, with a majority of the CXCL-8 response specific to the HBV X
peptide pool. CXCL-9 and CXCL-10 production in IHL-3 followed
an identical antigen-specific distribution (data not shown). This
suggests that there are liver resident, HBV-specific T cells capable of
responding to HBV antigens by producing CXCL-8.
The limited number of cells and responses precluded any firm
conclusions since CXCL-8 can also be produced by macrophages,
Kupffer cells, granulocytes as well as hepatocytes. Therefore, we used
immuno-fluorescence to confirm that CXCL-8 producing T cells are
present in the liver of chronic HBV patients. Biopsies from four
chronic HBV patients were stained with anti-CD3 and anti-CXCL-8.
Multiple CD3+/CXCL-8+ cells were detected in two separate
patients in multiple fields, confirming the presence of CXCL-8
producing T cells in the liver of chronic HBV patients (Fig. 1C).
No IL-17 production by HBV specific T cells
The absence of peptide-specific IL-17 production in the
intrahepatic samples may be due to the relatively limited number
of response detected overall or could be related to the fact that the
Figure 1. Chemokine production following HBV peptide stimulation of intrahepatic mononuclear cells. A) Cumulative amount of
chemokines produced in response to all HBV peptides in a representative HBV patient. B) Antigen distribution of CXCL-8 production from panel A. All
supernatants were harvested after 20 h culture and background from unstimulated wells was subtracted to give peptide specific concentrations. C)
Representative immunofluorescence staining of a biopsy from a chronic HBV patient with elevated ALT. Figure shows CD3 (red, left panels), CXCL-8
(green, middle panels) and merged images, including DAPI staining (right panels).
doi:10.1371/journal.pone.0023330.g001
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intrahepatic samples had relatively little inflammation (ALT
,150 U/L for all samples). To further investigate the possibility
of virus-specific IL-17 producing T cells we tested acute HBV
patients (5 ex vivo, 4 in vitro expanded) with serum levels of
alanine-aminotransferase (ALT), an enzyme released upon
hepatocyte damage, greater than 1000 U/L, chronic HBV
patients (6 ex vivo, 5 in vitro expanded) with elevated ALT (5/6
patient ALT .1000 U/L) and intrahepatic lymphocytes isolated
from chronic HBV patients (4 ex vivo) by IL-17-specific Elispot
using overlapping peptides covering the entire HBV proteome.
Some chronic HBV patients had elevated ALT at multiple time
points and thus were tested repeatedly (ex vivo n= 11; in vitro
n= 9).
We did not detect any HBV-specific IL-17 producing T cells in
acute or chronic HBV patients ex vivo or after in vitro expansion
(Fig. 2 A–E). Following SEB stimulation, we did not observe any
increase in non-specific IL-17+ T cells in acute HBV patients with
high ALT (.1000 U/L), chronic HBV patients with normal ALT
(,50 U/L), chronic HBV patients with raised ALT (.100 U/L)
or intrahepatic lymphocytes from chronic HBV patients compared
to that observed in healthy donors (Fig. 2F). Virus-specific cells
were present when screened for IFN-c (Fig. 3 & 4 and data not
shown) indicating that HBV-specific T cells are present but do not
produce IL-17.
CXCL-8 producing T cells in HBV patients
There is no CXCL-8 Elispot assay available and since CXCL-8
can be produced by many different cell types we tested T cell
CXCL-8 production using flow cytometry to be certain produc-
tion was from T cells. We first tested 3 acute HBV patients that
had longitudinal samples from onset to resolution. T cells were
expanded for 10 d using overlapping peptides and tested for IFN-c
and CXCL-8 production. IFN-c responses were detected to
peptides pools in all three patients. Two patients had small but
detectable populations of CXCL-8+/IFN-c+ T cell responses at
the onset of disease; one representative patient is shown in
figure 3A. CXCL-8+ T cells were only detectable to the
polymerase Pol-2 peptide pool at the onset of disease
(ALT=1520 U/L) and disappeared as liver inflammation subsid-
ed, whereas IFN-c+ responses remained detectable (Fig. 3A, top
row). CXCL-8 producing T cells comprised only a portion of the
IFN-c+ response and were not detectable in other responses within
the same patient (Env-2; Fig. 3A, middle row).
Since the frequency of CXCL-8+ T cells was small we tested
short-term T cell lines from 3 additional acute HBV patients,
where we identified individual peptide responses using IFN-c
Elispot (Figure S1), for peptide specific CXCL-8 production. T cell
lines from acute patients were stimulated with the indicated
peptides and CXCL-8 was measured in the supernatant after
overnight culture. CXCL-8 production was variable between
patients, and between responses within the same patient, but was
clearly detectable in response to peptide stimulation, whereas EBV
and CMV specific T cells expanded from 8 healthy donors were
all negative (Fig. 3B). These data confirm that virus-specific T cells
have the capacity to produce CXCL-8 but it was unclear whether
CXCL-8 production was an inducible function or represented a
distinct lineage that became undetectable as the T cell response
contracted with disease resolution.
IL-7 and IL-15 induce CXCL-8 production in HBV-specific
T cells
To determine if CXCL-8 production was an inducible
phenotype and, as hypothesized above, if exposure to IL-7 and
IL-15 could play a role we expanded PBMC from 6 acute/
resolved HBV patients in the presence of IL-2 alone or IL-2 plus
IL-7 and IL-15 and tested for HBV-specific CXCL-8 producing T
cells. T cells grown in IL-2 alone produced IFN-c but little or no
CXCL-8 (Fig. 4A). In contrast, cells from the same patient, grown
in IL-2+IL-7+IL-15 in parallel, showed a significant increase in
CXCL-8 producing T cells (Fig. 4B). Unlike before when CXCL-8
production was not observed in multiple responses within the same
patient and barely detectable after peptide stimulation, CXCL-8
production was much greater and a CXCL-8+ population could
be detected in all the IFN-c+ responses from this patient. In
Figure 2. No IL-17 producing T cells were found in HBV patients. Peptide-specific IL-17 elispot was performed using PBMC from acute HBV
patients (A) ex vivo or (B) after in vitro expansion and on chronic HBV patients with elevated ALT (C) ex vivo or (D) after in vitro expansion and on (E)
IHL from chronic HBV patients. F) Ex vivo stimulation with SEB to determine if the frequency of non-specific IL-17 producing cells was increased in
patients with active liver inflammation. All data expressed as spot forming units (SFU)/105 cells.
doi:10.1371/journal.pone.0023330.g002
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addition to IFN-c+/CXCL-8+ T cells, we also observed a
population of CXCL-8 single positive T cells. We also examined
whether IL-7 and IL-15 induced the production of IL-17 in these
cells but as demonstrated in figure 4C, even after in vitro
expansion in IL-7 and IL-15 HBV-specific T cells did not produce
IL-17. We were also able to further expand these cells in vitro and
demonstrate that this functional phenotype could be induced/
maintained in both CD4 (Fig. 4D) and CD8 (Fig. 4E) T cells.
Overall, for T cells expanded in IL-2 alone we detected 18 IFN-
c+ T cell responses distributed between all four HBV proteins
(Table 1). Of the 18 IFN-c+ responses, only three were IFN-c+/
CXCL-8+ (Table 1). In contrast, when T cells were expanded in
the presence of IL-7 and IL-15 we found that 14/15 (93%) of the
virus-specific responses detected were IFN-c+/CXCL-8+ (Table 1
and Fig. 4F). The culture conditions clearly altered the function of
HBV-specific CD8 and CD4 T cells and induced the ability to
produce CXCL-8. Even if cells were first expanded in IL-2 alone,
further stimulation in medium containing IL-2, IL-7 and IL-15
could induce this functional alteration (data not shown). When
antigen specific distribution of IFN-c+/CXCL-8+ T cells was
analyzed, we found that they were evenly distributed between the
different HBV proteins, similar to what was found in cells cultured
in IL-2 alone (Table 1). Thus, IFN-c/CXCL-8 producing virus-
specific T cells can be induced to encompass almost the entire
population of HBV-specific T cells given the appropriate
conditions.
Characterization of CXCL-8 producing T cells
To characterize the phenotype of CXCL-8 producing T cells
we stained for a panel of receptors that are associated with
intrahepatic T cells in HBV patients and CCR6, which is
generally found on IL-17 producing T cells. We expanded PBMC
from healthy donors for 7 d in IL-2, IL-7 & IL-15 using anti-CD3
and examined receptor expression on CXCL-8+ T cells after
mitogen stimulation. We found that the dominant population
within the CXCL-8+/CD3+ T cells expressed CXCR3 and
NKG2D (Fig. 5A). CCR5, CD161 and CD56 were also expressed
on 10–20% of CXCL-8+ T cells whereas CCR6 expression was
low.
To characterize their function we first determined which T cell
subset had the highest frequency of CXCL-8 producing T cells. As
seen in figure 5B, CXCL-8+ T cell frequency was significantly
higher in CD8 T cells compared to CD4 T cells. We then
analyzed the cytokine profile of CD8+/CXCL-8+ and CD4+/
CXCL-8+ T cells using polychromatic flow cytometry. CXCL-8+
T cells were multifunctional but the cytokine profiles differed
between the CD8 and CD4 T cells. The largest population within
the CD8 T cells (40% of CXCL-8+/CD8+ T cells) produced a
total of four cytokines CXCL-8, IFN-c, TNF-a, and GM-CSF
(Fig. 5C). CD8 T cells producing CXCL-8, IFN-c and TNF-a
represented a similar frequency (Fig. 5C). In contrast, the largest
population in the CD4 T cells produced CXCL-8, IL-17, and
TNF-a (35% of CXCL-8+/CD4+ T cells) followed by cells that
were capable of producing 5 different cytokines (Fig. 5D). The
dominant cytokine within the CXCL-8+/CD4+ T cells was IL-17,
suggesting that Th17 cells may produce CXCL-8.
Inducible CXCL-8 production in unrelated virus-specific T
cells
We determined if CXCL-8 production was unique to HBV-
specific T cells by testing the culture conditions (IL-2, IL-7 and IL-
15) on memory T cells specific for an unrelated virus. CMV-
specific T cells from healthy donors were expanded in different
combinations of IL-2, IL-7 and IL-15 and we monitored their
ability to produce IFN-c and CXCL-8 by intracellular cytokine
staining. Similar to HBV-specific T cells, culture in IL-2 alone
yielded IFN-c+ T cells but did not induce CXCL-8 production;
neither did IL-7 and IL-15 only weakly induced CXCL-8
production by CMV specific cells (Fig. 6). The combination of
IL-2/IL-7 did not boost CXCL-8 production over the individual
cytokines but the combination of IL-2 and IL-15 did increase
CXCL-8+ T cell frequency. However, culture in all three
cytokines induced the most robust CXCL-8 production by
CMV-specific T cells (Fig. 6). Detection of CXCL-8+ T cells
was not simply a consequence of detection limit. T cells cultured in
IL-7 alone, IL-15 alone and IL-2+IL-7 resulted in much higher
frequencies of IFN-c+ T cells (35–42%) but low/undetectable
Figure 3. T cell CXCL-8 production in acute HBV patients. A)
Longitudinal PBMC samples tested with pools of HBV peptides for
specific IFN-c and CXCL-8 production; Pol-2 peptide pool (top row)
produced CXCL-8, Env-2 (Middle row) produced only IFN-c, unstimu-
lated cells (bottom row) show the background at each time point. Dot
plots were gated on total T cells. B) CXCL-8 produced from short-term T
cell lines expanded from acute HBV patients +/2 1 mg/ml peptide for
20 h. Multiple responses for three separate patients are displayed. As
negative control, EBV and CMV-specific short-term T cell lines were
expanded from 8 healthy donors and analyzed for CXCL-8 production.
The mean CXCL-8 production is shown for the healthy donors.
doi:10.1371/journal.pone.0023330.g003
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frequencies of CXCL-8+ T cells compared to cells grown in IL-
2+IL-7+IL-15 (25% IFN-c+ and 1.1% CXCL-8+) These data
indicate that CXCL-8 production is not restricted to HBV-specific
T cells and is an inducible functional phenotype that can impact
other virus-specific T cell populations.
Discussion
Recent reports have demonstrated the functional plasticity of
memory T cells, where at least a small proportion of the memory
cell population can be reprogrammed based on environmental
queues [22]. This flexibility in T cell function likely helps tailor the
antiviral T cell response to the site of infection. In our study, we
examined virus-specific T cell function in the liver of chronic HBV
patients and longitudinally in patients during the changing
environment from disease onset to resolution. We identified a
population of HBV-specific T cells able to produce CXCL-8 in the
setting of liver inflammation; however, this function disappeared
as inflammation resolved in acute patients. Using cytokines that
have been identified in the inflammatory liver environment we
were able to re-induce CXCL-8 production not only in HBV-
specific responses but also unrelated CMV-specific responses from
healthy donors.
CXCL-8 production by T cells was previously a rare quality.
Examples of CXCL-8 producing T cells have only been described
in immune-mediated inflammatory skin reactions such as drug-
specific acute generalized exanthematous pustulosis (AGEP) and to
our knowledge there has been no such description of this function
in pathogen-specific T cells [13,14,29]. Despite the lack of
previous examples, we detected peptide-specific CXCL-8 produc-
tion from intrahepatic lymphocytes of chronic HBV patients and
from peripheral blood T cells in acute/resolved patients. After
culturing acute/resolved HBV patient PBMC in IL-7 and IL-15
we could detect CXCL-8 producing T cells in the majority of
HBV-specific responses. We attempted to use surface markers to
identify CXCL-8 producing T cells and delineate whether IL-7
and IL-15 were inducing a unique population of virus-specific T
cells or altering the function of classical memory T cells; however,
we were unable to ascertain a distinct phenotype to answer this
question. We did observe that if cells were first cultured in IL-2
alone for 10 d, further in vitro expansion in the presence of IL-7
Figure 4. IL-7 and IL-15 induce CXCL-8 production. Acute patient PBMC cultured in A) IL-2 alone or B) IL-2/IL-7/IL-15 were expanded with
peptides covering the entire HBV proteome and tested with peptide pools for IFN-c and CXCL-8 production. C) PBMC from the same patient
expanded in IL-2/IL-7/IL-15 were tested with peptide pools for IL-17 and CXCL-8 production. D) HBV-specific CD4 T cells and E) HBV-specific CD8 T
cells restimulated in IL-2/IL-7/IL-15 expand and maintain CXCL-8 production. F) Distribution of functional phenotypes of all HBV-specific T cell
responses detected in acute/resolved HBV patients after in vitro culture in IL-2 or IL-2/IL-7/IL-15.
doi:10.1371/journal.pone.0023330.g004
Table 1. Frequency and cytokine profile of T cell responses
from acute HBV patients.
Patient Acute/Resolved
Culture Condition IL-2 IL-2+IL-7+IL-15
cytokine profilea IFN-c+ c+/8+ IFN-c+ c+/8+
# responsesb 15/18 3/18 1/15 14/15
HBV antigen
Core 3 0 0 5
Env 4 1 1 4
Pol 7 2 0 5
X 1 0 0 0
aType of cytokine response detected IFN-c+= IFN-c+/CXCL-82; c+/8+= IFN-c+/
CXCL-8+.
bnumber of responses corresponding to cytokine profile out of total IFN-c+
responses detected.
doi:10.1371/journal.pone.0023330.t001
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and IL-15 could induce CXCL-8 production (data not shown),
suggesting that these cytokines are altering T cell function.
The fact that IL-7 and IL-15 were required to detect CXCL-8
producing T cells in nearly all HBV-specific responses suggests a
particular environment is necessary before virus-specific T cells
are licensed with such inflammatory function. IL-15 has been
associated with multiple inflammatory diseases [25,30,31], is up-
regulated following liver injury [32] and is increased in patients
with chronic hepatitis B and C infection [23,24,33]. Further-
more, IL-15 can be produced by hepatic stellate cells (Ito cells)
[34], a specialized liver-resident antigen presenting cell, while
IL-7 can be produced by hepatocytes [28]. Thus, it is possible
that the liver is a particularly well suited environment for the
induction of CXCL-8 producing virus-specific T cells. However,
it was clear from our experiments with CMV-specific T cells
that induction of CXCL-8 production is not limited to HBV-
specific T cells and IL-7 and IL-15 can alter the functional
profile of memory T cells to unrelated viruses in healthy
individuals.
There appeared to be lineage differences between CXCL-8+
CD8 and CD4 T cells. While a large proportion of the CXCL-8+
T cells expressed surface receptors consistent with a Th1/Tc1
profile, which was evident in the functional profile of CXCL-8+/
CD8+ T cells, a majority of the CXCL-8+/CD4+ T cells
produced IL-17. Chemokine receptor expression on CXCL-8+
T cells was not differentiated into CD4/CD8 but CXCL-8+ CD4
T cells represented a relatively small fraction of the total T cell
population, which was consistent with the low frequency of CCR6
detected on total CXCL-8+ T cells. However, it is important to
note that this functional phenotype, which was observed after
Figure 5. Characterization of CXCL-8+ T cells. A) Receptor expression on CXCL-8+ T cells from healthy donor PBMC expanded for 7 d in IL-2/IL-
7/IL-15. Graph shows the frequency of receptor expression on total CXCL-8+ T cells from three donors. B) Frequency of CD8 and CD4 CXCL-8+ T cells
in total T cell population from 5 healthy donors after in vitro expansion. C) Functional profile of C) CXCL-8+/CD8+ T cells and D) CXCL-8+/CD4+ T
cells. Shown are frequencies of cytokine profiles within the CD8/CXCL-8 or CD4/CXCL-8 from 4 healthy donors.
doi:10.1371/journal.pone.0023330.g005
Figure 6. Induction of CXCL-8 in CMV-specific CD8 T cells cultured for 10 d in the cytokine indicated above respective plots.
Following expansion, CMV-specific cells were stimulated with 1 mg/ml peptide and stained for CXCL-8 and IFN-c.
doi:10.1371/journal.pone.0023330.g006
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PMA/ionomycin stimulation, was not detected in any of the
antigen specific assays in our study.
We tested extensively for the presence of virus-specific IL-17
producing T cells in all of the assays, ex vivo and after in vitro
expansion, but were unable to find a significant HBV-specific
population by Elispot, intracellular cytokine staining or peptide
specific production in the supernatant of intrahepatic lymphocytes.
In addition to the lack of HBV-specific IL-17 production, we did
not observe an increase in non-specific IL-17 producing T cells
using Elispot after SEB stimulation in acute and chronic HBV
patients. We previously characterized cytokines detectable in the
serum of HBV patients and were unable to detect IL-1b or IL-6,
two cytokines that play a role in the development of Th17 cells
[12]. Therefore, the inflammatory environment during HBV
infection may not lend itself to Th17 differentiation. However, our
data on non-specific IL-17 production is in contrast to recent
reports suggesting that IL-17 producing T cells were increased in
chronic HBV patients with liver inflammation [20]. This
discrepancy could be due to the sample size or assays and
mitogens used to stimulate IL-17 producing T cells. Additional
studies, particularly in the intrahepatic compartment, will be
necessary to determine if IL-17 producing cells are involved in
HBV pathology but our data suggest that HBV-specific IL-17
producing T cells are not present in acute or chronic HBV
patients.
Overall, the goal of the current study was to characterize a
potential inflammatory profile that could exacerbate tissue and
organ inflammation in non-cytopathic viral infections. The exact
role of CXCL-8 in human liver inflammation is still not clear and
whether CXCL-8 producing T cells actually contribute to or
initiate the inflammatory process is an open question. However,
our data demonstrate that human virus-specific T cells have, or
can acquire through exposure to environmental factors, a
cytokine/chemokine profile capable of contributing to parenchy-
mal inflammation observed in non-cytopathic viral infection
[9,10,11,35].
Materials and Methods
Ethics Statement
This study was approved by the National University Hospital of
Singapore Institutional review board and the Singapore Ethics
Committee. Written informed consent was obtained from all
subjects.
Patients
Blood and liver specimens were collected with informed consent
from 30 patients (Blood from 12 acute/resolved HBV patients,
PBMC from 6 chronic patients plus 8 intrahepatic lymphocytes
and 4 biopsies from chronic patients) infected with HBV from the
Gleneagles Hospital and National University Hospital Singapore.
Eight subjects had clinical, biochemical and virological evidence of
acute hepatitis B infection (ALT levels .10 times the upper limits
of normal, detection of HBsAg and serum anti-HBc IgM and
HBsAg clearance within 2 months from clinical onset of hepatitis).
PBMC from four patients were collected during the resolved phase
following acute HBV infection. The 18 chronic hepatitis B patients
studied had clinical, biochemical and virological evidence of
chronic HBV infection (HBV-DNA+, HBsAg+, HBeAg+, and
elevated levels of ALT).
All studied patients were negative for antibodies to hepatitis C
virus (HCV) and delta virus. Virological assessment, HBsAg,
HBeAg, anti-HBs, anti-HBc IgG and IgM, anti-HBe, anti-HDV,
anti-HCV, were determined by commercial enzyme immunoassay
kits (Abbott Labs, IL, USA; Ortho Clinical Diagnostic, Johnson &
Johnson). Serum HBV-DNA was quantified by PCR (Cobas
Amplicor test; Roche Diagnostic, Basel, Switzerland).
Cell lines
Short-term T cell lines were grown for 10 d in AIM-V+2%
human AB serum (Invitrogen, Carlsbad, CA) supplemented with
20 U/ml IL-2+/210 ng/ml IL-7 and IL-15 (R&D systems).
Briefly, PBMC were thawed and 20% of cells were pulsed with
10 mg/ml 15mer overlapping peptides spanning the entire HBV
proteome (Mimotopes, Clayton, Victoria) for 1 h at 37uC, washed
and mixed with remaining PBMC in 1 ml of medium and grown
in 24 well plates. After 10 d expansion cells were tested using
Elispot and intracellular cytokine staining with pools of overlap-
ping peptides (1 core, 1 X, 2 envelope, 4 polymerase pools). For
defined epitopes, 2.56105 cells/well on 96 well round bottom
plates were stimulated with 1 mg/ml peptide and expanded in the
media described above. To determine the surface and functional
phenotype of CXCL-8 producing T cells, PBMC of healthy
donors were expanded with anti-CD3 (OKT-3, eBioscien-
ce)+20 U/ml IL-2+10 ng/ml IL-7 and IL-15 for 7 d.
Peptides
15mer peptides, overlapping by 10 amino acids, covering the
entire HBV proteome were based on the HBV genotype C
(GenBank: AB112063) and D (GenBank: AF121241) sequences
(Mimotopes). Overlapping peptides were pooled according tor
their protein and included up to 45 individual peptides; 1 core, 1
X, 2 envelope (Env), and 4 polymerase (Pol) pools were made.
Defined amino acid epitopes HBV surface (HBs) 335-43
(WLSLLVPFV); HBs370-79 (SIVSPFIPLL); CMVpp65 495–504
(NLVPMVATV) were purchased from Genscript (Piscataway,
NJ). Additional individual peptide responses were identified via
IFN-c Elispot screening (data not shown).
Enzyme-Linked Immunosorbent Spot Assay (ELISPOT)
ELISPOT assays were performed as previously described using
peptides covering the entire proteome of HBVgenC or HBVgenD
[6]. T cell responses were analyzed directly ex vivo or after 10 d in
vitro expansion with 16105 cells/well. Briefly, 96-well plates
(Multiscreen-HTS; Millipore, Billerica, MA) were coated over-
night at 4uC with 2.5 mg/ml capture mouse anti-human IL-17
antibody (eBio64CAP17; eBioscience). The plates were then
washed with PBS, blocked and a total of 16105 cells were added
to each well. HBV peptides from the patients’ respective genotype
were added to a final concentration of 2 mg/ml and plates were
incubated for 18 hours at 37uC. Following the incubation, IL-17
spot forming units (SFU) were detected using 0.25 mg/ml anti-
human IL-17 MAb (eBio64DEC17; eBioscience) followed by
incubation with streptavidin-alkaline phosphatase (Mabtech,
Sweden). The plates were washed and 50 ml of alkaline
phosphatase substrate (5-bromo-4-chloro-3-indolyl phosphate–
nitro blue tetrazolium chloride [BCIP-NBT]; KPL, Gaithersburg,
MD) was added. Two wells were left without peptide as negative
controls. Positive control was 10 mg/ml staphylococcal enterotoxin
B (SEB; Sigma-Aldrich, St. Louis, MO). IL-17 secreting cells were
expressed as (SFU) per 16105 cells. Assays were considered
positive when SFU was above 5.
Flow cytometry
For intracellular cytokine staining short term T cell lines were
stimulated with 1–5 mg/ml of defined epitopes or overlapping
peptide pools covering Core, X, envelope, polymerase for 6 h in
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the presence of 10 mg/ml brefeldin A (Sigma-Aldrich, St. Louis,
MO). Following incubation, cells were surface labeled with CD8-
PeCy7 or CD4-PeCy7 (BD Biosciences, San Jose, CA) and fixed
using Cytofix/Cytoperm (BD Biosciences). Cells were stained with
anti-IFN-c-APC, TNF-a-Alexa488, anti-CXCL-8-PE (BD Biosci-
ences) or anti-IL-17-Alexa488 (eBioscience) for 30 min on ice,
washed and fixed in 1% formaldehyde. Data acquisition was
performed using a BD FACs Canto flow cytometer.
T cells from healthy donors expanded in IL-2, IL-7 and IL-15
were stimulated with PMA/ionomycine for 6 h in the presence of
10 mg/ml brefeldin A after 7 d in vitro culture. Following
stimulation cells were stained with CXCR3-APC, CCR5-APC,
NKG2D-APC, CD161-APC, CD56-PeCy7 (BD Biosciences) or
CCR6-APC (R&D Systems) and then fixed in cytofix/cytoperm.
After fixation T cells were stained with anti-CXCL-8-PE. CXCL-
8+ T cells were gated and analyzed for surface receptor expression.
Isotype control antibodies were used as negative control to define
positive populations. To examine the functional profile of CXCL-
8+ T cells we stimulated T cells from healthy donors expanded in
IL-2, IL-7 and IL-15 with PMA/ionomycin for 6 h in the presence
of 10 mg/ml brefeldin A. T cells were labeled with anti-CD3-Q605
(Invitrogen), anti-CD8-APC-Cy7 and anti-CD4-PerCp (BD Biosci-
ences) and fixed using cytofix/cytoperm. T cells were stained
with anti-CXCL-8-PE, anti-IFN-c-V450, anti-TNF-a-PeCy7 (BD
Biosciences), anti-IL-17-Alexa488 and anti-GM-CSF-Alexa647
(eBioscience). Samples were acquired on BD LSR-II flow cytometer
and data was analyzed in FACs Diva software.
Chemokine/Cytokine measurement
Cell culture supernatants were tested for chemokine production,
IL-17A and IL-10 using the Cytometric bead assay (BD
Biosciences). Supernatants were collected after 20 h from 105
cells (intrahepatic lymphocytes or short-term T cell line) +/2
stimulation by individual peptides or peptide pools. Chemokines
tested were CXCL-8 (IL-8), CCL-5 (RANTES), CXCL-9 (MIG),
CCL-2 (MCP-1) and CXCL-10 (IP-10).
Isolation of intrahepatic lymphocytes
Intrahepatic lymphocytes were isolated from liver samples
collected from hepatic resections of hepatocellular carcinoma nodules
from chronically infected HBV patients. Non-tumor tissue surround-
ing HCC were used to isolate intrahepatic lymphocytes. Tissue
sections were dissociated by mechanical disruption using scalpels and
then using an Ultra-Turrax tube drive (IKA, Wilmington, NC).
Samples were digested with 1 U/ml Liberase blendzyme 3 (Roche,
Basel, Switzerland) for 15 min at 37C with stirring. Samples were
washed with HBSS centrifuged at 4006g for 10 min to remove
Liberase enzyme. Tissue homogenate was re-suspended in HBSS and
large debris and hepatocytes were separated by differential
centrifugation at 856g for 2 min. Differential centrifugation was
repeated twice and supernatants taken from differential centrifuga-
tion were pelleted at 4006g for 10 min. The tissue sample pellet was
re-suspended in RPMI and depleted of large debris by passage
through a 100 mm vacuum driven filter (Millipore, Billerica, MA).
Filtered samples were layered over Ficoll-Paque Plus (GEHealthcare,
Piscataway, NJ) and intrahepatic lymphocytes were isolated by
density gradient centrifugation.
Immunofluorescent staining
Patient biopsies were thawed, dried at room temperature and
fixed with acetone. Slides were blocked with 10% normal goat
Serum (DAKO) for 30 min at room temperature then incubated
with mouse monoclonal anti-human CXCL-8 (BD Pharmigen;
Clone G265-8) in combination with rabbit anti-human CD3
(DAKO) followed by AlexaFluor594-conjugated anti-rabbit and
AlexaFluor488-conjugated anti-mouse Abs (Invitrogen). Nuclei
were stained with DAPI (Invitrogen). Images were acquired using
Olympus IX 81 inverted microscope and ImagePro software.
Supporting Information
Figure S1 T cell responses to individual peptides from acute
HBV patients. Acute HBV patients were stimulated in vitro with
15mer overlapping peptides covering the entire HBV proteome
for 10 d and screened for HBV specific T cell responses using 2
dimensional IFN-c Elispot. Short-term lines were stimulated with
5 mg/ml of each individual peptide identified from the IFN-c
elispot for 5 h and screened using intracellular cytokine staining or
CD107a degranulation assay to confirm individual peptide
responses. Remaining cells from the 10 d culture were stimulated
overnight with confirmed peptides and supernatants were
harvested to screen for CXCL-8 production in figure 3B.
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